Hydrophobic Imbalance in the Cytoplasmic Domain of Phospholamban Is a Determinant for Lethal Dilated Cardiomyopathy*§

Delaine K. Ceholski1,2, Catharine A. Trieber§1, and Howard S. Young‡3
From the 1Department of Biochemistry, University of Alberta, Edmonton, Alberta T6G 2H7, Canada and the 2National Institute for Nanotechnology, University of Alberta, Edmonton, Alberta, Canada T6G 2M9

Background: Heterozygous mutations in phospholamban cause lethal dilated cardiomyopathy.

Results: Hydrophobic substitutions in the cytoplasmic domain of phospholamban lead to loss of inhibition and a dominant negative effect on SERCA.

Conclusion: Hydrophobic changes in the cytoplasmic domain of phospholamban appear to be one determinant for hereditary dilated cardiomyopathy.

Significance: This may provide a prediction model for genetic testing of patients with heart failure.

The sarco(endo)plasmic reticulum calcium ATPase (SERCA) and its regulatory partner phospholamban (PLN) are essential for myocardial contractility. Arg9 → Cys (R9C) and Arg14 deletion (R14del) mutations in PLN are associated with lethal dilated cardiomyopathy in humans. To better understand these mutations, we made a series of amino acid substitutions in the cytoplasmic domain of PLN and tested their ability to inhibit SERCA. R9C is a complete loss-of-function mutant of PLN, whereas R14del is a mild loss-of-function mutant. When combined with wild-type PLN to simulate heterozygous conditions, the mutants had a dominant negative effect on SERCA function. A series of targeted mutations in this region of the PLN cytoplasmic domain (8TRSAIRR14) demonstrated the importance of hydrophobic balance in proper PLN regulation of SERCA. The results reveal that the change in hydrophobicity resulting from the R9C and R14del mutations is sufficient to explain the loss of function and persistent interaction with SERCA. Hydrophobic imbalance in the cytoplasmic domain of PLN appears to be a predictor for the development and progression of dilated cardiomyopathy.

Approximately one in three cases of congestive heart failure are due to dilated cardiomyopathy (DCM), where the defining features are left ventricular dilation, contractile dysfunction, and weakened pumping force. Familial DCM accounts for one-third to one-half of these cases, and more than 40 genes have been implicated in disease (1). Although the genetic diversity of DCM involves many cellular processes, mutations that depress force generation are prominent. Because force generation and calcium homeostasis are coupled in the myocardium, it is not surprising that disease-associated mutations have been found in calcium-handling proteins of the sarcoplasmic reticulum (SR).

SR calcium stores provide the majority of calcium used in muscle contraction-relaxation. During relaxation, an ATP-dependent calcium pump (SERCA) in the SR is essential for the recovery of calcium. The reuptake of calcium by SERCA determines the rate of relaxation and the size of the calcium store available for subsequent contractions. In cardiac muscle, a second protein called phospholamban (PLN) acts as a reversible inhibitor of SERCA and thereby modulates contractility in response to physiological cues (2, 3). SERCA inhibition by PLN is a dynamic process that depends on the cytosolic calcium concentration as well as the phosphorylation and oligomeric states of PLN. The synergistic effect is a modulation of calcium reuptake and cardiac contractility that can be finely tuned in response to activity, stress, or disease (4).

Dysregulation of SERCA by PLN is linked to heart failure. In humans, abnormal SERCA/PLN ratios and chronic SERCA inhibition are common features of heart failure (5–8), despite a diverse array of root causes. More directly, mutations have been found in the PLN gene itself. A Leu39-stop nonsense mutation has been described as a PLN null (9, 10), where heterozygous individuals develop hypertrophy and homozygous individuals develop DCM. A loss-of-function Arg9 → Cys (R9C) missense mutation has been implicated in lethal DCM (11). Although the loss of function associated with this mutant may lead to disease, the main effect is proposed to be an abnormal interaction with protein kinase A (PKA). An Arg14 deletion (R14del) mutation has been linked to both mild (12) and severe (13, 14) DCM. This mutant is thought to be a superinhibitor of SERCA in the
heterozygous but not the homozygous condition (13). Finally, Arg9 → Leu (R9L) and Arg9 → His (R9H) have recently been identified in heart failure patients (15), yet they remain uncharacterized. Interestingly, there have been no homozygous patients identified with any of these mutations except Leu39- stop. Nonetheless, the available mutants demonstrate that both loss of SERCA inhibition and chronic SERCA inhibition can cause DCM.

The development of therapeutic solutions for DCM requires detailed knowledge of the underlying disease-associated mechanisms (16). Toward this goal, we characterized the functional properties of PLN mutants in isolation with SERCA. The R9C mutation replaces a positive charge with a cysteine, and at first glance, the aberrant chemistry of a sulfhydryl could contribute to disease (17). In a similar line of reasoning, the R14del mutation removes a positive charge, shortens the cytoplasmic domain, and disrupts the PKA recognition motif of PLN. Herein, we made a series of amino acid substitutions in the cytoplasmic domain of PLN. In proteoliposomes with SERCA, we found that Arg9 → Leu and Thr8 → Cys mutations mimicked the functional consequences of R9C, and an Arg14 → Ala mutation mimicked R14del. The results from many additional mutations indicated that hydrophobic balance in the cytoplasmic domain of PLN is a critical determinant of function. Importantly, when mutant and wild-type PLN were combined with SERCA, the R9C and R14del mutants had a dominant negative effect on SERCA activity. Taken together, hydrophobicity and persistent association with SERCA are contributing factors in PLN mutations known to cause lethal DCM.

EXPERIMENTAL PROCEDURES

Mutagenesis and Expression of PLN—Human PLN was expressed and purified as described (18). Mutants were confirmed by DNA sequencing (TAGC Sequencing, University of Alabama) and MALDI-TOF mass spectrometry (Institute for Biomolecular Design, University of Alberta). To phosphorylate PLN, purified PLN was solubilized in detergent and treated with the catalytic subunit of PKA (Sigma-Aldrich) (19).

Co-reconstitution of SERCA and PLN—SERCA1a was purified from rabbit skeletal muscle SR (20, 21) and co-reconstituted with PLN as described (19). The purified proteoliposomes yielded a final molar ratio of 1 SERCA, 4.5 PLN, and 120 lipids. The SERCA and PLN concentrations were determined by quantitative SDS-PAGE (22).

Cardiac SR—Cardiac SR membranes were purified from canine and porcine ventricles (23), and the concentrations of both SERCA2a and PLN were quantitated (22, 24, 25). Using affinity-purified SERCA1a and recombinant PLN as protein standards, incremental amounts of each protein were run next to cardiac SR membranes on the same SDS-polyacrylamide gel. Colloidal Coomassie Blue G250-stained gels were digitized, and the SERCA2a bands were quantitated and compared with a SERCA1a standard curve. To determine the amount of PLN in cardiac SR, Western blots were probed with an anti-PLN antibody (2D12, Abcam) followed by an IR800 dye-labeled secondary antibody (LI-COR Biosciences), and the PLN bands were quantitated and compared with a recombinant PLN standard curve.

Activity Assays—Calcium-dependent ATPase activities of the proteoliposomes were measured by a coupled enzyme assay (26). All co-reconstituted PLN mutants were compared with a negative control (SERCA alone) and a positive control (SERCA in the presence of wild-type PLN). The mutants investigated included alanine substitutions from Lys to Thr17 of PLN; a series of amino acid substitutions of Thr8, Arg9, Ser10, and Arg13; and deletion of Arg14 (Table 1). A minimum of three independent reconstitutions and activity assays were performed for each mutant, and the ATPase activity was measured over a range of calcium concentrations (0.1–10 μM). The calcium concentration at half-maximal activity (KCa) and the maximal activity (Vmax) were calculated based on non-linear least-squares fitting of the activity data to the Hill equation using Sigma Plot (SPSS Inc., Chicago, IL). Errors were calculated as the S.E. for a minimum of three independent reconstitutions. Comparison of KCa and Vmax was carried out using one-way analysis of variance (between subjects), followed by the Holm-Sidak test for pairwise comparisons.

Kinetic Simulations—Reaction rate simulations have been described for the transport cycle of SERCA (27, 28), and we have previously used this approach to understand SERCA inhibition by PLN mutants (29). As before, we performed a global non-linear regression fit of the model to each plot of SERCA ATPase activity versus calcium concentration using Dynafit (Biokin Inc., Pullman, WA). The kinetic simulations for SERCA in the absence and presence of wild-type PLN provided starting points for optimization of the fit for SERCA in the presence of phosphorylated and mutant PLN.

RESULTS

Under normal physiological conditions, the cytoplasmic domain of PLN contributes to SERCA inhibition and provides a means of reversing inhibition through its phosphorylation. The R9C and R14del mutations in the cytoplasmic domain alter both the inhibitory capacity of PLN and the regulation of PLN function by phosphorylation. Herein, we wished to gain mechanistic insight into how mutations in the cytoplasmic domain of PLN affect SERCA inhibition and lead to DCM. Our first objective was to compare the disease-causing mutations with phosphorylation of PLN, which is the main physiological mechanism for alleviating SERCA inhibition. We next performed alanine-scanning mutagenesis of the cytoplasmic domain of PLN (residues 3–17 (30)) in an attempt to replicate the behavior of the lethal mutations. Finally, a more focused mutagenesis strategy was used to uncover the physicochemical properties that confer dysfunctional characteristics on PLN and lead to DCM.

Reconstitution versus Cardiac SR—The proteoliposomes used herein contain both SERCA1a and PLN oriented with their cytoplasmic domains on the external surface of the vesicles at lipid/protein ratios similar to those of cardiac SR membranes (19, 29). Although there may be subtle differences in the interaction of PLN with SERCA1a versus SERCA2a (31), the skeletal muscle isoform is well established as a surrogate for structural and functional studies of the complex (for examples, see Refs. 32–36 and Refs. 19, 23, 29, and 37, respectively). Herein, we wished to ensure that the PLN-SERCA ratio in our
co-reconstituted proteoliposomes was physiologically relevant. The reported PLN/SERCA molar ratios include values of 0.2 (38), –2 (39–41), –4 (24, 25). Most studies agree that there is at least a 2-fold excess of PLN, yet there is a lack of consistency between observations. We measured the concentrations of both SERCA2a and PLN in cardiac SR (supplemental Fig. S1). The calculated molar ratio of PLN per SERCA was 4.1 for both canine and porcine cardiac SR. This ratio matches the PLN content of our proteoliposomes and is in excellent agreement with values reported for rabbit, rat, and porcine cardiac SR. This ratio matches the PLN content of our proteoliposomes and is in excellent agreement with values reported for rabbit, rat, and porcine cardiac SR. This ratio matches the PLN content of our proteoliposomes and is in excellent agreement with values reported for rabbit, rat, and porcine cardiac SR. This ratio matches the PLN content of our proteoliposomes and is in excellent agreement with values reported for rabbit, rat, and porcine cardiac SR.

R9C, R14del, and Phosphorylated PLN—The PKA-mediated phosphorylation of PLN is the best understood mechanism for alleviating SERCA inhibition, and we wished to compare this mechanistic framework with the disease-associated mutants of PLN. To accomplish this, we measured the calcium-dependent ATPase activity of SERCA alone and in the presence of wild-type PLN, phosphorylated PLN, R9C, and R14del (Fig. 1 and Table 1). As expected, inclusion of wild-type PLN in proteoliposomes with SERCA decreased the $K_{Ca}$ value 1.9-fold and increased the $V_{max}$ value of SERCA 1.5-fold. Phosphorylation of PLN at Ser16 alleviated the inhibition and restored the $K_{Ca}$ of SERCA to control levels (Fig. 1A). Inclusion of R9C in proteoliposomes had no effect on the $K_{Ca}$ and $V_{max}$ of SERCA, which is in agreement with the initial characterization of this mutant (11). Inclusion of R14del in proteoliposomes decreased the $K_{Ca}$ and increased the $V_{max}$ of SERCA. The effect of R14del on the $K_{Ca}$ of SERCA was somewhat less than that of wild-type PLN, yet this mutant was clearly inhibitory (67% of wild-type inhibition). Interestingly, it was apparent from the ATPase isotherm data (Fig. 1 and Table 1) that the two non-inhibitory forms of PLN (phosphorylated wild type and R9C) had a persistent effect on SERCA function. This is consistent with previous demonstrations that phosphorylated PLN (43–45) and R9C (17) retain the ability to physically interact with SERCA.

To provide a mechanistic framework for the disease-associated mutants, the ATPase activity measurements were fit to the reaction scheme for SERCA calcium binding (Fig. 2) (27). SERCA calcium binding occurs as cooperative steps linked by a conformational transition ($E_{Ca} \leftrightarrow E_{Ca}^{'}$). PLN slows this conformational change via an effect on $B_{rev}$, thereby reducing the $K_{Ca}$ of SERCA (28, 29). For wild-type PLN, phosphorylated PLN, R9C, and R14del, we observed effects on all three calcium-binding steps, particularly $A_{for}$, $B_{rev}$, and $C_{for}$ (29). The primary effect was on $B_{rev}$, yet a decrease in the forward rate constant for binding of the second calcium ion ($C_{for}$) contributed to SERCA inhibition. Phosphorylation of PLN restored the $K_{Ca}$ of SERCA, yet significant inhibition persisted at low calcium concentrations (Fig. 1A). Whereas $B_{rev}$ decreased to near control levels following phosphorylation, the value for $C_{for}$ remained low and
Cytoplasmic Mutations of Phospholamban and SERCA Dysregulation

FIGURE 2. Part of the reaction scheme for calcium transport by SERCA. Calcium binding involves three distinct steps: binding of the first calcium ion ($K_{Ca}$ and $B_{Ca}$), a conformational change that establishes cooperativity ($B_{rev}$ and $A_{rev}$), and binding of the second calcium ion ($C_{Ca}$ and $C_{rev}$). Bottom, summary of the effects observed in kinetic simulations of SERCA in the absence (SERCA) and presence of wild-type PLN (PLN), phosphorylated PLN (ph-PLN), the Arg9 → Cys mutant (R9C), and the Arg14 deletion mutant (R14del).

FIGURE 3. ATPase activity as a function of calcium concentration for SERCA in the presence of an equimolar mixture of R9C and wild-type PLN (dashed line). SERCA in the absence (solid line) and presence (gray line) of wild-type PLN is shown for comparison. The data are normalized to $V_{max}$, and each data point is the mean ± S.E. (error bars) (n ≥ 4). The $V_{max}$, $K_{Ca}$, and $n_H$ values are given in Table 1. Right, the potential outcomes of this experiment are schematically shown.

provided a mechanism for the residual inhibitory activity of phosphorylated PLN (Fig. 2 and supplemental Table S1). In terms of the kinetic simulations, the R9C mutant closely mimicked phosphorylated PLN, whereas the partial inhibition by the R14del mutant was due to an effect on $B_{Ca}$. As a first step in examining this question, we mutated residues 3–17 of PLN to alanine, co-reconstituted each mutant with SERCA, and measured the calcium-dependent ATPase activity of R14del and wild-type PLN did not result in superinhibition of SERCA. Although we did not observe superinhibition in this simplified experimental system, the complex sequelae associated with disease could result in chronic SERCA suppression. In addition, other environmental or genetic factors may be involved because both mild (12) and severe DCM (13, 14) have been linked to the R14del mutation.

Alanine Substitutions in Cytoplasmic Domain of PLN—In general, mutations in the cytoplasmic domain of PLN tend to have a much smaller effect on SERCA inhibition (30) than mutations in the transmembrane domain (29, 46). These experimental observations contrast sharply with findings in hereditary DCM, where mutations are more common in the cytoplasmic domain of PLN. What physicochemical characteristics define the disease-associated mutations and underlie disease? As a first step in examining this question, we mutated residues 3–17 of PLN to alanine, co-reconstituted each mutant with SERCA, and measured the calcium-dependent ATPase activity of the proteoliposomes (Fig. 4A and Table 1). Collectively, the alanine mutants were consistent with the notion that the cytoplasmic domain of PLN makes a small contribution to SERCA inhibition. Averaging the kinetic parameters for the alanine substitutions, we obtained a loss-of-function mutant in the transmembrane domain of PLN, Arg14 → Ala (N34A) (46). The persistent effect on SERCA seen for the R9C and R14del mutants was not observed with N34A (supplemental Fig. S2). From these data, there were two main conclusions. First, in the presence of wild-type PLN, the R9C and R14del mutants were capable of a dominant negative effect on SERCA function. Second, when separated from other cellular components in proteoliposomes, the combination of R14del and wild-type PLN did not result in superinhibition of SERCA. In the absence of superinhibition in this simplified experimental system, the complex sequelae associated with disease could result in chronic SERCA suppression. In addition, other environmental or genetic factors may be involved because both mild (12) and severe DCM (13, 14) have been linked to the R14del mutation.

Despite the limited contribution of the cytoplasmic domain of PLN to SERCA inhibition, a few mutations had a more substantial impact. The largest effects on the $K_{Ca}$ of SERCA were observed for alanine substitution of Lys3, Thr5, Arg14 (partial loss-of-function mutants), and Thr17 (gain-of-function
null
Cytoplasmic Mutations of Phospholamban and SERCA Dysregulation

hydrophobic balance in the cytoplasmic domain of PLN is a critical determinant for proper function. In support of this notion, all of the most severe loss-of-function mutants studied herein (R9C, R9I, R9L, R9M, R9V, T8C, S10C, and R13I) replaced a polar residue with a hydrophobic residue.

Kinetic simulation of the ATPase isotherms revealed further insight into the severe loss of function observed for the disease-associated and -mimicking mutations (supplemental Table S1). For instance, the complete loss of function associated with the R9C and R9L mutants appeared to be analogous to the phosphorylation of wild-type PLN. All three calcium binding steps were affected, with an increase in $A_{\text{for}}$ (binding of the first calcium ion) and $C_{\text{for}}$ (binding of the second calcium ion) and a decrease in $B_{\text{rev}}$ (SERCA conformational change). The net result was that all three calcium binding steps were more favorable for transport. Additionally, as expected from the ATPase isotherms (Fig. 5), the R9C and R9L mutants had a persistent effect on SERCA rate constants (implying that they remain physically associated) despite being complete loss-of-function mutants. This is consistent with FRET studies demonstrating that R9C retains the ability to interact with SERCA despite the loss of inhibitory function (17).

DISCUSSION

Mutations in human PLN have been linked to hereditary cardiomyopathies. These include Leu39-stop in the transmembrane domain of PLN (29, 46). All three calcium binding steps were affected, with an increase in $A_{\text{for}}$ (binding of the first calcium ion) and $C_{\text{for}}$ (binding of the second calcium ion) and a decrease in $B_{\text{rev}}$ (SERCA conformational change). The net result was that all three calcium binding steps were more favorable for transport. Additionally, as expected from the ATPase isotherms (Fig. 5), the R9C and R9L mutants had a persistent effect on SERCA rate constants (implying that they remain physically associated) despite being complete loss-of-function mutants. This is consistent with FRET studies demonstrating that R9C retains the ability to interact with SERCA despite the loss of inhibitory function (17).

Nonetheless, the kinetic simulations reveal an effect of PLN on $B_{\text{rev}}$ in the reaction scheme for SERCA (28) as well as an effect on $C_{\text{for}}$. Considering the suggestion that PLN dissociates from SERCA following calcium binding (48, 49), the simulations support a physical interaction that persists at least through all three calcium binding steps of the reaction cycle (Fig. 2).

Nonetheless, the above discussion largely refers to the inhibitory interaction of the PLN transmembrane domain. How does the cytoplasmic domain fit into this model, with particular emphasis on phosphorylation and the disease-associated mutations? It is difficult to envision how mutation or phosphorylation of the cytoplasmic domain of PLN negates the inhibitory interaction of the transmembrane domain with SERCA. One model for the phosphorylation of PLN suggests that it restores SERCA function by dissociating the inhibitory complex (50, 51). An alternative model for the phosphorylation of PLN suggests that it restores the apparent calcium affinity of SERCA by altering the structural interaction between the two proteins, yet the two proteins remain associated (43, 44, 52, 53). Our data for SERCA alone versus SERCA in the presence of phosphorylated PLN (Fig. 1) demonstrated that the ATPase activity isotherms were not equivalent and that phosphorylated PLN had a persistent effect on SERCA. The inference is that phosphorylated PLN can remain physically associated with SERCA in a non-inhibitory complex.

Disease-associated Mutations and Development of DCM—The PLN mutants R9C and R14del are known to be associated with lethal DCM. In the case of R9C, the underlying mechanism is reported to be a dominant effect on PKA phosphorylation via the β-adrenergic pathway (11). In the case of R14del, the underlying mechanism is reported to be superinhibition of SERCA in the heterozygous state based on co-transfection in HEK-293 cells (13); however, the homozygous transfection of R14del resulted in partial inhibition of SERCA. This latter result is consistent with our data for R14del as a partial inhibitor of SERCA, even in the presence of wild-type PLN. Nonetheless, it is reasonable to expect that these changes in the function of PLN could contribute to myocardial calcium dysregulation and the development or progression of heart disease. The available data suggest that either loss or gain of PLN function can contribute to the development of DCM, even in a heterozygous background where wild-type PLN is present. Herein, one surprising finding was that the R9C and R14del mutants preferentially affect SERCA in the presence of equal amounts of the wild-type protein (designed to approximate heterozygous conditions). This is best exemplified by the data for R9C (Fig. 3). With coreconstituted proteoliposomes containing SERCA and equal amounts of mutant and wild-type PLN, there were several possible functional outcomes: (i) wild-type PLN may preferentially affect SERCA, resulting in normal SERCA inhibition; (ii) wild-type and mutant PLN may equally affect SERCA, resulting in an intermediate level of SERCA inhibition; and (iii) the mutant may preferentially affect SERCA, resulting in SERCA inhibition that resembles the mutant. For both R14del and R9C, the effect of the mutant on SERCA function dominated in the presence of the wild-type protein.

Focusing on R9C, what is it about this mutation that causes loss of function and a persistent effect on SERCA? We con-
Cytoplasmic Mutations of Phospholamban and SERCA Dysregulation

In Support of Hydrophobic Imbalance Hypothesis—Given the similarity to R9C, we anticipated that the R9L mutation might eventually be found in the human population. This was confirmed during the final stages of our work when two individuals in a cohort of 1,014 Brazilian patients with heart failure were found to harbor the R9L mutation (15). One of these R9L patients presented with idiopathic DCM followed by death at 30 years of age, reminiscent of what we know about R9C patients (11). An R9H mutation was also found, although the disease relevance of this mutant remains unclear.

Acknowledgments—We thank Angela Brigley and Leah Stables for technical assistance and Dr. Ludovic Renault and Przemek Gorski for helpful discussions.

REFERENCES

1. Dellefave, L., and McNally, E. M. (2010) The genetics of dilated cardiomyopathy. Curr. Opin. Cardiol. 25, 198–204
2. Kirchberber, M. A., Tada, M., and Katz, A. M. (1975) Phospholamban. A regulatory protein of the cardiac sarcoplasmic reticulum. Recent Adv. Stud. Cardiac Struct. Metab. 5, 103–115
3. Simmerman, H. K., Collins, J. H., Theibert, J. L., Wegener, A. D., and Jones, L. R. (1986) Sequence Analysis of Phospholamban. Identification of Phosphorylation Sites and Two Major Structural Domains. J. Biol. Chem. 261, 13333–13341
4. MacLennan, D. H., and Kranias, E. G. (2003) Phospholamban. A crucial regulator of cardiac contractility. Nat. Rev. Mol. Cell Biol. 4, 566–577
5. Hasenfuss, G., Reinecke, H., Studer, R., Meyer, M., Pieske, B., Holtz, J., Holubarsch, C., Posival, H., Just, H., and Drexler, H. (1994) Relation between myocardial function and expression of sarcoplasmic reticulum Ca\(^{2+}\)-ATPase in failing and nonfailing human myocardium. Circ. Res. 75, 434–442
6. Meyer, M., Schillinger, W., Pieske, B., Holubarsch, C., Heilmann, C., Posival, H., Kuwajima, G., Mikoshiba, K., Just, H., and Hasenfuss, G. (1995) Alterations of sarcoplasmic reticulum protein isoforms in human dilated cardiomyopathy. Circulation 92, 778–784
7. Minamisawa, S., Sato, Y., Tatsuguchi, Y., Fujino, T., Imamura, S., Uetsuka, Y., Nakazawa, M., and Matsuoka, R. (2003) Mutation of the phospholamban promoter associated with hypertrophic cardiomyopathy. Biochem. Biophys. Res. Commun. 304, 1–4
8. Haghigi, K., Chen, G., Sato, Y., Fan, G. C., He, S., Kolokathis, F., Pater, L., Paraskevaidis, L., Jones, W. K., Dorn, G. W., 2nd, Kremastinos, D. T., and Kranias, E. G. (2008) A human phospholamban promoter polymorphism in dilated cardiomyopathy alters transcriptional regulation by glucocorticoids. Hum. Mutat. 29, 640–647
9. Haghigi, K., Kolokathis, F., Pater, L., Lynch, R. A., Ashi, M., Gramolini, A. O., Fan, G. C., Tsiapras, D., Hahn, H. S., Adamopoulos, S., Liggett, S. B., Dorn, G. W., 2nd, MacLennan, D. H., Kremastinos, D. T., and Kranias, E. G. (2003) Human phospholamban null results in lethal dilated cardiomyopathy revealing a critical difference between mouse and human. J. Clin. Invest. 111, 869–876
10. Landstrom, A. P., Adekola, B. A., Bos, J. M., Ommen, S. R., and Ackerman, M. J. (2011) PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases. Summary of the literature and implications for genetic testing. Am. Heart J. 161, 165–171
11. Schmitt, J. P., Kamisago, M., Ashi, M., Li, G. H., Ahmad, F., Mende, U., Kranias, E. G., MacLennan, D. H., Seidman, J. G., and Seidman, C. E. (2003) Dilated cardiomyopathy and heart failure caused by a mutation in phospholamban. Science 299, 1410–1413
12. DeWitt, M. M., MacLeod, H. M., Soliven, B., and McNally, E. M. (2006) Phospholamban R14 deleletion results in late-onset, mild, hereditary dilated cardiomyopathy. J. Am. Coll. Cardiol. 48, 1396–1398
13. Haghigi, K., Kolokathis, F., Gramolini, A. O., Wagggoner, J. R., Pater, L., Lynch, R. A., Fan, G. C., Tsiapras, D., Parekh, R. R., Dorn, G. W., 2nd, MacLennan, D. H., Kremastinos, D. T., and Kranias, E. G. (2006) A mutation in the human phospholamban gene, deleting arginine 14, results in lethal, hereditary cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 103, 1388–1393
Cytoplasmic Mutations of Phospholamban and SERCA Dysregulation

14. Posch, M. G., Perrot, A., Geier, C., Boldt, L. H., Schmidt, G., Lehrnhu00df, H. B., Hetzer, R., Dietz, R., Gutberlet, M., Havmark, W., and Oczelik, C. (2009) Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes. *Heart Rhythm* 6, 480–486

15. Medeiros, A., Biagi, D. G., Sobreira, T. J., de Oliveira, P. S., Negrão, C. E., Mansur, A. J., Krieger, J. E., Brum, P. C., and Pereira, A. C. (2011) Mutations in the human phospholamban gene in patients with heart failure. *Am. Heart J.* 162, 1088–1095.e1

16. Rapti, K., Chaanine, A. H., and Hajjar, R. J. (2011) Targeted gene therapy for the treatment of heart failure. *Can. J. Cardiol.* 27, 265–283

17. Ha, K. N., Masterson, L. R., Hou, Z., Verardi, R., Walsh, N., Veglia, G., and Robia, S. L. (2011) Lethal Arg9Cys phospholamban mutation hinders Ca\(^{2+}\)-ATPase regulation and phosphorylation by protein kinase A. *Proc. Natl. Acad. Sci. U.S.A.* 108, 2735–2740

18. Douglas, J. L., Triebel, C. A., Afara, M., and Young, H. S. (2005) Rapid, high-yield expression and purification of Ca\(^{2+}\)-ATPase regulatory proteins for high-resolution structural studies. *Protein Expr. Purif.* 40, 118–125

19. Triebel, C. A., Douglas, J. L., Afara, M., and Young, H. S. (2005) The effects of mutation on the regulatory properties of phospholamban in co-reconstituted membranes. *Biochemistry* 44, 3289–3297

20. Eletr, S., and Inesi, G. (1972) Phospholipid orientation in sarcoplasmic reticulum membranes. Spin-label ESR and proton NMR studies. *Biochim. Biophys. Acta* 282, 174–179

21. Stokes, D. L., and Green, N. M. (1990) Three-dimensional crystals of Ca\(^{2+}\)-ATPase from sarcoplasmic reticulum. Symmetry and molecular packing. *Biophys. J.* 57, 1–14

22. Young, H. S., Jones, L. R., and Stokes, D. L. (2001) Locating phospholamban in co-crystals with Ca\(^{2+}\)-ATPase by cryoelectron microscopy. *Biophys. J.* 81, 884–894

23. Reddy, L. G., Jones, L. R., Pace, R. C., and Stokes, D. L. (1996) Purified, reconstituted cardiac Ca\(^{2+}\)-ATPase is regulated by phospholamban but not by direct phosphorylation with Ca\(^{2+}\)/calmodulin-dependent protein kinase. *J. Biol. Chem.* 271, 14964–14970

24. Ferrington, D. A., Yao, Q., Squier, T. C., and Bigelow, D. J. (2002) Comparable levels of Ca-ATPase inhibition by phospholamban in slow-twitch skeletal and cardiac sarcoplasmic reticulum. *Biochemistry* 41, 13289–13296

25. Negash, S., Chen, T. L., Bigelow, D. J., and Squier, T. C. (1996) Phosphorylation of phospholamban by cAMP-dependent protein kinase enhances interactions between Ca-ATPase polypeptide chains in cardiac sarcoplasmic reticulum membranes. *Biochemistry* 35, 11247–11259

26. Warren, G. B., Toon, P. A., Birdsall, N. J., Lee, A. G., and Metcalfe, J. C. (1974) Reconstitution of a calcium pump using defined membrane components. *Proc. Natl. Acad. Sci. U.S.A.* 71, 622–626

27. Inesi, G., Kurzmack, M., and Lewis, D. (1988) Kinetic and equilibrium characterization of an energy-transducing enzyme and its partial reactions. *Methods Enzymol.* 157, 154–190

28. Cantilina, T., Sagara, Y., Inesi, G., and Jones, L. R. (1993) Comparative studies of cardiac and skeletal sarcoplasmic reticulum ATPases. Effect of phospholamban antibody on enzyme activation. *J. Biol. Chem.* 268, 17018–17025

29. Triebel, C. A., Afara, M., and Young, H. S. (2009) Effects of phospholamban transmembrane mutations on the calcium affinity, maximal activity, and cooperativity of the sarcoplasmic reticulum calcium pump. *Biochemistry* 48, 9287–9296

30. Toyofuku, T., Kurzydlowski, K., Tada, M., and MacLennan, D. H. (1994) Amino acids Glu-2 to Ile-18 in the cytoplasmic domain of phospholamban are essential for functional association with the Ca-ATPase of sarcoplasmic reticulum. *J. Biol. Chem.* 269, 3088–3094

31. Hou, Z., and Robia, S. L. (2010) Relative affinity of calcium pump isoforms for phospholamban quantified by fluorescence resonance energy transfer. *J. Mol. Biol.* 402, 210–216

32. Reddy, L. G., Autry, J. M., Jones, L. R., and Thomas, D. D. (1999) Co-reconstitution of phospholamban mutants with the Ca-ATPase reveals dependence of inhibitory function on phospholamban structure. *J. Biol. Chem.* 274, 7649–7655
Phospholamban binds with differential affinity to calcium pump conformers. *J. Biol. Chem.* **286**, 35044–35050

54. Lockamy, E. L., Cornea, R. L., Karim, C. B., and Thomas, D. D. (2011) Functional and physical competition between phospholamban and its mutants provides insight into the molecular mechanism of gene therapy for heart failure. *Biochem. Biophys. Res. Commun.* **408**, 388–392

55. Chen, Z., Stokes, D. L., and Jones, L. R. (2005) Role of leucine 31 of phospholamban in structural and functional interactions with the Ca$^{2+}$ pump of cardiac sarcoplasmic reticulum. *J. Biol. Chem.* **280**, 10530–10539

56. Liu, L. P., and Deber, C. M. (1998) Guidelines for membrane protein engineering derived from *de novo* designed model peptides. *Biopolymers* **47**, 41–62